ASH Clinical Practice Guidelines on Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease

In 2024, in response to long-standing member interest, ASH approved a plan to develop clinical practice guidelines on Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease. Like other ASH guidelines, these new guidelines will be developed using methods that meet the highest standards for rigor and trust. The development process will include formation of an expert panel, systematic reviews of available evidence, structured recommendations, and public review.